Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease

Simple item page
dc.catalogadorjlo
dc.contributor.authorArab Verdugo, Juan Pablo
dc.contributor.authorDíaz Piga, Luis Antonio
dc.contributor.authorRehm, Jürgen
dc.contributor.authorIm, Gene
dc.contributor.authorArrese, Marco
dc.contributor.authorKamath, Patrick S.
dc.contributor.authorLucey, Michael R.
dc.contributor.authorMellinger, Jessica
dc.contributor.authorThiele, Maja
dc.contributor.authorThursz, Mark
dc.contributor.authorBataller, Ramon
dc.contributor.authorBurton, Robyn
dc.contributor.authorChokshi, Shilpa
dc.contributor.authorFrancque, Sven M.
dc.contributor.authorKrag, Aleksander
dc.contributor.authorLackner, Carolin
dc.contributor.authorLee, Brian
dc.contributor.authorLiangpunsakul, Suthat
dc.contributor.authorMacClain, Craig
dc.contributor.authorMandrekar, Pranoti
dc.contributor.authorMitchell, Mack C.
dc.contributor.authorMorgan, Marsha Y.
dc.date.accessioned2025-03-07T12:05:53Z
dc.date.available2025-03-07T12:05:53Z
dc.date.issued2025
dc.description.abstractIn this position statement, we explore the intricate relationship between alcohol intake and metabolic dysfunction in the context of the 2023 nomenclature update for steatotic liver disease (SLD). Recent and lifetime alcohol use should be accurately assessed in all patients with SLD to facilitate classification of alcohol use in grams of alcohol per week. Alcohol biomarkers (i.e., phosphatidylethanol), use of validated questionnaires (i.e. AUDIT-C [alcohol use disorders identification test consumption]), and collateral information from friends and relatives could help facilitate differentiation between alcohol-related liver disease (ALD) per se and liver disease with both metabolic and alcohol-related components (MetALD). Heavy alcohol use can contribute to cardiometabolic risk factors such as high blood pressure, hypertriglyceridaemia, and hyperglycaemia. As a result, caution should be exercised in the application of only one metabolic dysfunction criterion to diagnose MASLD, as suggested in the 2023 nomenclature document, particularly in individuals exceeding weekly alcohol use thresholds of 140 g for women and 210 g for men. This is particularly important in those individuals with isolated high blood pressure, hypertriglyceridaemia, or hyperglycaemia, where the disease process may be driven by alcohol itself. Additionally, metabolic dysfunction and alcohol use should be reassessed over time, especially after periods of change in risk factor exposure. This approach could ensure a more accurate prognosis and effective management of SLD, addressing both metabolic and alcohol-related factors.
dc.format.extent13 páginas
dc.fuente.origenSCOPUS
dc.identifier.doi10.1016/j.jhep.2024.11.028
dc.identifier.issn1600-0641
dc.identifier.scopusidSCOPUS_ID:85214534495
dc.identifier.urihttps://doi.org/10.1016/j.jhep.2024.11.028
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/102419
dc.information.autorucEscuela de Medicina; Arab Verdugo, Juan Pablo; 0000-0002-8561-396X; 132745
dc.information.autorucEscuela de Medicina; Diaz Piga, Luis Antonio; 0000-0002-8540-4930; 179253
dc.language.isoen
dc.nota.accesocontenido parcial
dc.revistaJournal of Hepatology
dc.rightsacceso restringido
dc.subjectAlcohol-related liver disease
dc.subjectAlcoholic cirrhosis
dc.subjectAlcoholic liver disease
dc.subjectPublic health
dc.subject.ddc600
dc.subject.deweyTecnologíaes_ES
dc.titleMetabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease
dc.typeartículo
sipa.codpersvinculados132745
sipa.codpersvinculados179253
sipa.trazabilidadSCOPUS;2025-01-19
Files
Collections
Artículos de revistas